Pharmaceutical drug testing is the meticulous exploration of a compound's safety, efficacy, and potential side effects, marking a pivotal phase in the journey from discovery to market. This intricate process unfolds in a series of carefully designed trials, each serving a distinct purpose in unravelling the compound's impact on the human body. The journey begins with preclinical testing, where researchers delve into the compound's behaviour in the laboratory and animal models. This phase unveils insights into safety profiles, potential dosage ranges, and initial efficacy.
Upon successful preclinical evaluations, the compound progresses to clinical trials, a multi-phase endeavour involving human subjects. Phase 1 focuses on safety and dosage, Phase 2 delves into efficacy, and Phase 3 expands to larger populations, further validating the drug's effectiveness and monitoring for rare side effects. Regulatory bodies meticulously review the accumulated data, assessing the compound's risk-benefit profile before granting approval for market release. Post-marketing surveillance continues the scrutiny, ensuring ongoing safety and efficacy monitoring.
The evolution of pharmaceutical drug testing mirrors a meticulous orchestration of scientific inquiry, ethical considerations, and regulatory diligence. Each trial, from petri dish to patient, contributes to the collective endeavour of bringing safe and effective medications to those in need.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia